Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IV BCAA + Lactulose for HE in ACLF
NCT04238416Phase 1Completed
- Sponsor
- Post Graduate Institute of Medical Education and Research
- Start
- Nov 2019
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of Branchamin in hepatic encephalopathy (HE) (2 arms), sponsored by Post Graduate Institute of Medical Education and Research. Primary endpoints: Improvement of Survival at 28 days and Improvement of encephalopathy by ≥ 1 grade at 72 hours. Started Nov 2019; status: completed.
02
Drugs
Branchamin
03
Conditions
hepatic encephalopathy (HE)
Beyond the preview
Go deeper on NCT04238416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04238416.